Drugs & Targets FDA grants accelerated approval to selpercatinib for pediatric RET-altered metastatic thyroid cancer or solid tumors May 31, 2024Vol.50 No.22
Drugs & Targets FDA acknowledges BLA resubmission for Zolbetuximab for HER2- gastric or GEJ adenocarcinoma with CLDN18.2-positive tumors May 31, 2024Vol.50 No.22
Drugs & Targets FDA advisory committee recommends approval of Shield blood test for colorectal cancer screening May 24, 2024Vol.50 No.21
Drugs & Targets FDA withdraws accelerated approval of infigratinib for metastatic cholangiocarcinoma with FGFR2 May 24, 2024Vol.50 No.21
Drugs & Targets FDA forms OCE Equity Program to improve clinical trial access May 24, 2024Vol.50 No.21
Capitol Hill Sen. Durbin weighs in on the controversy about dosage of Amgen drug sotorasib May 17, 2024Vol.50 No.20By Paul Goldberg
Drugs & Targets FDA, EMA grant Orphan Drug Designation to Carthera for carboplatin with SonoCloud technology in glioma May 17, 2024Vol.50 No.20
Guest Editorial OCE’s Project 5 in 5 seeks to inspire pragmatic innovation May 10, 2024Vol.50 No.19By Steven C. Cunningham, Donna R. Rivera, Richard Pazdur, Kelly J. Norsworthy and Jennifer Gao
